🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

SER SER

Company Profile ↓
$2.23
-57.84% 1Y
Mkt Cap$24.01M
P/E-1.17
P/B-655.88
52W High$5.65
52W Low$1.28
Book Value$-0.00
EPS (TTM)$-1.91

Company Overview

SER (SER) is a publicly traded company listed on with a market capitalization of $24.01M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.18.

Growth & Price Performance

Stock Price Performance

1 Year:-57.84%
6 Months:-19.20%
3 Months:+23.89%
1 Month:+2.76%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 22% of range
$1.28 $5.65
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)60.04 · Neutral
Price Performance
1M+2.76%
3M+23.89%
6M-19.20%
1Y-57.84%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 60.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.17
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-0.00
Price to Book
-655.88
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.58
EPS (TTM)
$-1.91

Balance Sheet & Liquidity

Debt/Equity
0.18
Quick Ratio
-
Current Ratio
1.71
Debt
$3.14M
Total Assets
$27.30M
Current Assets
$26.47M
Working Capital
$2.52M

Ownership

Promoter Holding
85.96%
Chg in Prom Hold
-
FII / Inst Holding
9.84%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$0
EBITDA
$-18.91M
Free Cash Flow
$-18.01M
Operating Cash Flow
$-17.95M
Shares Outstanding
10.77M
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 239.00K464.00K380.00K388.00K380.00K411.00K89.00K45.00K69.00K56.00K37.00K24.00K5.00K12.00K9.00K30.00K7.00K29.00K5.00K51.00K14.00K-00000
Cost of Revenue ---------------------------
Gross Profit 130.00K385.00K384.00K325.00K327.00K362.00K88.00K42.00K52.00K53.00K24.00K22.00K4.00K6.00K4.00K9.00K4.00K34.00K---------
Operating Expenses ----------------------5.86M5.57M6.39M6.21M6.28M
Operating Income -3.55M-2.13M-2.20M-3.12M-3.44M-3.28M-3.01M-2.37M-2.40M-2.19M-2.21M-1.67M-2.05M-1.59M-1.55M-962.00K-945.00K-1.46M-2.32M-3.87M-5.31M--5.86M-5.57M-6.39M-6.21M-6.28M
EBITDA -----------------------4.80M-6.44M-4.57M-3.10M-6.68M
Interest Expense ----------------------09.00K6.00K198.00K189.00K
Pretax Income -----------------------4.82M-6.46M-4.59M-3.32M-6.89M
Tax Provision ----------------------0---7.00K
Net Income -235.00K-1.93M-2.15M-3.13M-3.09M-3.22M-3.19M-2.69M-2.54M-2.09M-2.47M-1.96M-2.71M-2.62M-2.44M1.66M808.00K1.75M-15.02M5.20M1.41M--4.81M-6.45M-4.58M-3.34M-6.90M
Diluted EPS --------------0.07-0.060.200.110.23-5.380.510.13--0.49-0.66-0.45--0.58
R&D Expense 1.59M1.38M1.33M1.34M1.65M1.45M1.22M935.00K653.00K324.00K481.00K275.00K396.00K259.00K162.00K399.00K479.00K603.00K1.11M1.59M2.42M-2.95M3.15M3.65M-3.20M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.40M1.40M1.73M361.00K-500.00K3.00M00
Cost of Revenue ---------
Gross Profit 1.24M1.03M1.48M335.00K-----
Operating Expenses -----2.77M6.13M17.05M24.02M
Operating Income -6.66M-11.24M-12.56M-10.10M--2.27M-3.13M-17.05M-24.02M
EBITDA ------2.60M5.92M-10.49M-18.91M
Interest Expense -----15.88K558.00K526.00K213.00K
Pretax Income ------2.68M5.27M-11.21M-19.20M
Tax Provision --------18.00K
Net Income -6.58M-7.50M-12.15M-10.87M--2.68M5.27M-11.14M-19.18M
Diluted EPS ------1.230.63-1.51-1.91
R&D Expense 5.78M5.83M5.90M3.71M1.46M1.02M2.39M7.48M13.15M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -9.63M10.67M7.44M3.92M-858.04K8.97M6.72M6.95M
Current Assets ------548.58K7.62M5.68M6.08M
Cash & Equivalents 259.00K7.38M6.71M2.35M527.00K-532.23K7.62M3.67M3.06M
Inventory ----------
Receivables -----1.11K0---
Total Liabilities -1.31M2.44M4.83M9.32M-38.64M41.26M6.22M6.99M
Current Liabilities ---3.30M5.36M-437.69K1.41M2.37M3.56M
Long Term Debt ------1.62M2.98M-2.95M
Total Debt ------1.81M3.44M268.00K3.14M
Total Equity -22.38M7.28M7.45M2.22M-5.12M--37.78M-32.29M641.00K-37.00K
Shares Outstanding ------8.41M8.41M9.42M10.77M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -6.29M-8.00M-10.16M-7.82M--2.08M-2.48M-17.14M-17.95M
Investing Cash Flow 5.00K1.33M-361.00K-20.00K-980.94K-504.00K-22.00K-59.00K
Financing Cash Flow 13.28M6.00M6.26M5.96M-1.31M10.07M13.21M17.41M
Capital Expenditure -1.00K-21.00K-641.00K-20.00K--9.68K-504.00K-22.00K-59.00K
Free Cash Flow -6.29M-8.02M-10.80M-7.84M--2.09M-2.98M-17.16M-18.01M
Net Change in Cash -----217.38K7.09M-3.95M-602.00K

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 88.0%73.9%85.9%92.8%-----
Operating Margin % -474.6%-805.5%-726.8%-2,797.8%--454.1%-104.3%--
Net Margin % -468.7%-537.4%-703.4%-3,009.7%--536.4%175.6%--
ROE % -90.4%-100.7%-548.0%212.4%-7.1%-16.3%-1,738.1%51,843.2%
ROCE % ---303.0%705.3%--540.1%-41.4%-391.2%-709.0%

Shareholding Pattern

Insiders
85.96%
Institutions
9.84%
Public Float
70.07%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SER

Yahoo Finance Fri, 24 Jul 2026

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, to…

Yahoo Finance hu, 23 Jul 2026

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the…

Yahoo Finance Wed, 22 Jul 2026

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

HUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, tod…

Yahoo Finance hu, 09 Jul 2026

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Data Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 - Dosing of additional patients in Cohort 1 is underway at sites in the US and Australia - Company is on …

Yahoo Finance ue, 30 Jun 2026

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

HUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology…

Yahoo Finance hu, 14 May 2026

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 - – Closed $21.2 million private placement financing to support continued advancemen…

SER — Frequently Asked Questions

What is the current share price of SER?

As of 2026-08-05 17:25 PDT, SER trades at $2.23 on NASDAQ/NYSE. Its 52-week range is $1.28 to $5.65.

What is the market capitalisation of SER?

SER has a market capitalisation of $24.01M on NASDAQ/NYSE.

What is the P/E ratio of SER?

SER trades at a trailing price-to-earnings (P/E) ratio of -1.17. Its price-to-book (P/B) ratio is -655.88.

Is SER a good stock to buy?

This page provides a data-driven analysis of SER, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space